Shattuck Labs, Inc. (STTK)
- Previous Close
9.90 - Open
9.63 - Bid 9.38 x 100
- Ask 9.86 x 100
- Day's Range
9.59 - 9.70 - 52 Week Range
1.33 - 11.11 - Volume
1,695 - Avg. Volume
329,380 - Market Cap (intraday)
461.244M - Beta (5Y Monthly) 2.13
- PE Ratio (TTM)
-- - EPS (TTM)
-2.05 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.75
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
www.shattucklabs.comRecent News: STTK
Performance Overview: STTK
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STTK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STTK
Valuation Measures
Market Cap
470.75M
Enterprise Value
344.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
254.52
Price/Book (mrq)
3.25
Enterprise Value/Revenue
207.80
Enterprise Value/EBITDA
-3.92
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.40%
Return on Equity (ttm)
-54.41%
Revenue (ttm)
1.66M
Net Income Avi to Common (ttm)
-87.3M
Diluted EPS (ttm)
-2.05
Balance Sheet and Cash Flow
Total Cash (mrq)
130.62M
Total Debt/Equity (mrq)
2.90%
Levered Free Cash Flow (ttm)
-49.61M